Logo-aim
Arch Iran Med. 2021;24(5): 354-363. doi: 10.34172/aim.2021.52

Original Article

Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran

Maryam Jameshorani 1, Homayoon Vahedi 2, Anahita Sadeghi 2, Ali Reza Sima 2, Amir Anushiravani 2, Helia Nateghi beige 2, Masoud M. Malekzadeh 2, Shokoofeh Naserinejad 2, Sudabeh Alatab 2 *

Cited by CrossRef: 2

1- Dalal R, Sharma P, Bains K, Pruce J, Allegretti J. 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure. 2024;30(3):395 [Crossref]
2- Gialouri C, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int. 2023;43(3):421 [Crossref]

SCImago Journal & Country Rank

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.